Quebec Introduces Innovative HPV Screening for Cervical Cancer

A new screening program for cervical cancer is set to be implemented in Quebec, focusing on the use of HPV testing to enhance early detection. This initiative comes in response to the ongoing challenges posed by cervical cancer, particularly among women under 50 years of age. Each year, approximately 430 Canadians die from cervical cancer, according to the Canadian Cancer Society.

Jennifer Curran’s experience underscores the importance of effective screening. During her pregnancy, she received a diagnosis of cervical cancer, which was advanced enough to require both radiation and chemotherapy following her cesarean section. Curran, now 44, noted that she exhibited no symptoms prior to her diagnosis. “I didn’t get a chance to linger in being sad for myself because I had this little baby to take care of,” she said, reflecting on her dual role as a new mother and cancer patient.

The primary risk factor for cervical cancer is infection with the human papillomavirus (HPV). Until recently, the standard method for screening was the Pap test; however, there is a significant shift towards utilizing HPV tests. Dr. Annie Leung, a gynecologic oncologist at the McGill University Health Centre (MUHC), has been leading research on a new screening method that is more sensitive and accurate. This test can detect HPV before it leads to abnormal cell changes, potentially saving women from invasive treatments.

“The possibility that I would need to do surgery to remove their uterus and cervix has huge implications on what their future looks like,” Dr. Leung explained. Although Pap tests are still recommended, the introduction of self-testing—where women can collect samples at home—aims to make screening more accessible, particularly in northern and Indigenous communities where cervical cancer rates are notably high.

“With new technology, we’re able to detect the virus itself,” Dr. Leung stated. “Before we even see abnormal cells, we can identify and detect the virus that causes those changes.” Self-screening initiatives have already been launched in British Columbia and Ontario, with plans for rollout in Quebec by mid-2026.

The MUHC Foundation, which is funding Dr. Leung’s research, has committed to raising $5 million for women’s health initiatives, which have historically received limited funding. Kim Cavener, who directs strategic giving at the foundation, highlighted a concerning fact: “Women’s health research receives only 7 percent of federal health research funding in Canada.”

Curran is actively supporting the foundation’s efforts, sharing her story to encourage others to seek HPV testing. She believes that had she been able to access such a test earlier, her health journey might have taken a different path. “Had I had that test available to me at the time, my story could have been very, very different,” she stated.

Fortunately, Curran’s story has a positive ending. Her daughter is approaching her fifth birthday, and both mother and child are healthy. As Quebec prepares to enhance its cervical cancer screening approach, the hope is that more women will receive timely interventions, improving outcomes and reducing the impact of this preventable disease.